AACR Annual Meeting 2023

AACR Annual Meeting 2023

April 14-19, 2023 | Orlando, FL, USA

Decoding the tumor microenvironment

The AACR Annual Meeting is the premier gathering for the cancer research community, bringing together scientists, clinicians, and other healthcare professionals from around the globe to share the most recent breakthroughs and advancements in cancer research and treatment. The 2023 meeting will take place in Orlando, and we are thrilled to contribute with our Spotlight Theater, scientific poster presentations and exciting new technologies at our booth.

With a specific emphasis on spatial biology, we will highlight our cutting-edge solutions for ultrahigh-content imaging and light sheet microscopy, in addition to showcasing our solutions for solid tumor dissociation, cell isolation, cell culture, cell analysis, and cell manufacturing.

Your thoughts count – visit us at our booth to complete our survey and to go into the running for one of our daily prizes! See you in Orlando!

Orange County Convention Center, Orlando, Florida
Miltenyi Biotec booth #1433
April 16–19, 2023 | Exhibit opening hours
Sunday 1:00 p.m.–5:00 p.m.
Monday 09:00 a.m.–5:00 p.m.
Tuesday 09:00 a.m.–5:00 p.m.
Wednesday 09:00 a.m.–12.00 p.m. 

Spotlight Theater

MACSima™ Imaging Platform - Applying spatial biology to advance cancer therapy

The advent of spatial biology promises to change how we see biological systems; where we can expect to uncover more hidden and astounding contexts to understand nature’s complexity like never before.

Join our Spotlight Theater to gain valuable insight into how our innovative spatial biology technology, the MACSima Imaging Platform, supports the advancement of cancer immunotherapies by unraveling the intricacy of the tumor microenvironment (TME) through high-protein plexity analysis – since content without context is just noise.

Monday, April 17, 2023
12:30–1:30 p.m.
Theater C
Visualizing Cancer to Instruct Precision Immunotherapy

Speaker: Dr. Christian Seitz, Head of  Advanced Cellular Therapies Lab, University Children's Hospital Tübingen, Tübingen, Germany

A comprehensive understanding of the immunophenotype, including antigen landscape, cellular composition, extracellular matrix, intratumoral heterogenicity and immune evasive setup, all in the spatial context, is indispensable to create evidence-based combinatorial immunotherapies and instruct next-generation CAR-T engineering for solid cancers.

The MACSimaTM spatial biology platform provides a powerful “plug and play” analytic tool to address these clinically crucial questions. We have established and validated comprehensive antibody panels exceeding 150 marker for both, fresh frozen and FFPE tissues, including target antigens, cell lineage, and functional state phenotyping, druggable immune checkpoint molecules and extracellular matrix components. These panels were applied to primary tumor samples of various cancer entities, resulting in highly coherent and reproducible data sets that were further cross-validated and aligned with established single cell technologies. The holistic view on tissue sections allows the identification of complex spatially restricted events, as shown for T cell as well as CAR-T cell interaction with myeloid cells, limiting infiltration and effector function in both primary tumor samples and disease models. By integrating the MACSima device in our clinical workflow, we were able to demonstrate feasibility for “on-the-fly” diagnostics to assist therapeutic decisions. In conclusion, the MACSima spatial biology solution, including the imaging platform and the established analytic workflows, provides a user-friendly and powerful tool to transform complex tissue analysis and paves the way to multimodal precision immunotherapy.

Speaker information
Christian Seitz, M.D., is a pediatric hematologist/oncologist at the University Children’s Hospital Tübingen, Germany. He studied medicine (2007–2014) at the universities in Ulm and Frankfurt as well as at the National Cancer Institute in Bethesda, MD, USA. He received his doctorate, Dr. med., from the Goethe University Frankfurt. In 2014, he started his clinical training in pediatrics under Rupert Handgretinger at the University Children’s Hospital Tübingen, focusing on stem cell transplantation and cellular therapies and was board certified in 2020. His scientific work is focused on the development and clinical translation of modular chimeric antigen receptor (CAR) technologies and the interaction of CAR T cells in the tumor microenvironment.

Read more …
Introduction to the MACSima™ Imaging System

Speaker: Robert Pinard, PhD. Director of Sequencing Chemistry & Molecular Technologies, Miltenyi Biotec

Introduction to the MACSima Imaging System — a fully automated ultra-high content imaging system that is founded on the principles of fluorescence microscopy. With its MICS technology (MACSima Imaging Cyclic Staining) the instrument allows for the study of 200+ markers on one sample without a complicated experiment set-up, allowing for multiparameter staining/detection of various antigens in one single staining cycle. Coupled with the MACS iQ® View data analysis software, this spatial biology platform is vital for understanding complexities such as the tumor microenvironment.  

Speaker information
Dr. Robert Pinard earned his PhD in Biochemistry at the University of Montreal, Canada in 1998 and did his post-doctoral studies at the University of Vermont (USA) in the Molecular Genetics department.  In 2001 he started his industry career when he joined Molecular Staging, a spin-off of Yale University, as a Senior Research Scientist and later on as the Group Leader for the gene profiling/clinical service team. From 2005 to 2006, Dr. Pinard held a position at 454 Life Science where he worked on emulsion PCR technology. In 2006, after the acquisition of 454 by Roche Pharmaceuticals, he joined another start-up, HistoRx, where he held the position of Director of Pharma Services and Analytical Methods and was a consultant until 2009. In 2008, he moved to Massachusetts with his family, and in 2009 he took a position at Correlagen Diagnostics. At Correlagen, he was closely involved in the development of their cardiac genetic test (CardioGeneScan®). The company was acquired by LabCorp of America who commercialized the test that is now known as GeneSeq® Cardio.  In 2016 he joined QIAGEN as a Senior Scientist and later on as the Associate Director of R&D, managing the development and optimization of their Next Generation Sequencing (NGS) automated platform. The NGS division and team was acquired by Miltenyi Biotec in 2019 where Dr Pinard is now the Director of Sequencing Chemistry & Molecular Technologies managing a team working on the development of NGS and multiomics automated platforms.

Read more …

Scientific posters

We're thrilled to announce that our team has once again submitted a collection of scientific posters that are sure to spark thought-provoking discussions. 

Pre-clinical evaluation of novel folate receptor 1 directed CAR T cells for high grade serous ovarian cancer

Presenter: Dr. Christoph Herbel 
April 17, 2023, 01:30 p.m.–05:00 p.m. 
Poster section 37
 Poster board number 9
Unlocking primary cell culture for more relevant in vitro models

Presenter: Dr. Benjamin Theek 
April 16, 2023, 01:30 p.m.–12:30 p.m.
 Poster section 2
Poster board number 24 
High-spatial-resolution multi-omics analysis of cancer tissues

Presenter: Robert Pinard, Ph.D.
April 18, 2023, 01:30 p.m. –5:00 p.m.
Poster section 43
Post board number 18
Analysis of the immune microenvironment and tumor-infiltrating immune cells across different solid tumors by combined spatial transcriptomics and proteomics
Presenter: Julia Femel, PhD
April 18, 2023 1:30 p.m. - 5:00 p.m. 
 Poster section 43
Poster board number 8
Fully human CD20 and CD19 dual-targeting CAR-T cells mediate long-term remissions and protection from tumor rechallenge in vivo

Presenter: Peirong Hu, Ph.D. 
April 17, 2023 1:30 p.m. - 5:00 p.m. 
Poster section 37
Poster board number 18


Our technologies can help you to unravel the complexity of the TME and enable high-quality multiomics analysis. Take a look at our novel imaging instruments for a deeper understanding.



Culture primary tumor cells with preserved parental features

Nutrient composition matters! Primary tumor cell cultures are ideal in vitro tumor models. They represent cellular heterogeneity as well as molecular features of the parental tumor. The challenge is providing conditions that allow non-selective growth without inducing any genomic, transcriptomic, or metabolomic changes. Luckily, our TumorMACS® Media contains a long list of growth factors to generate these distinct culture conditions for primary tumor cells. You're welcome.

Stop refining, start culturing

Contact us

Do you want to get in contact with us? Send your inquiry to:

Dr. Lorenz Fülle, Global Product Manager